Immunogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines

Pediatric Infectious Disease Journal

Volumn 28, Issue SUPPL. 4, 2009, Pages

  Wysocki, Jacek ^a   Tejedor, Juan C ^b   Grunert, Dutlef ^c   Konior, Ryszard ^d   Garcia Sicilia, Jose ^e   Knuf, Markus ^f   Bernard, Laurence ^g   Dieussaert, Ilse ^g,h   Schuerman, Lode ^g  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b HOSPITAL DE MÓSTOLES   (Spain)

^c Praxis   (Germany)

^d Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^h GSK   (Belgium)

Author keywords

ELISA; Opsonophagocytic activity; Pneumococcal conjugate vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; MENINGITIS VACCINE; MENINGOCOCCUS VACCINE; MENITORIX; PNEUMOCOCCAL NON TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CARRIER PROTEIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; GLPQ PROTEIN, HAEMOPHILUS INFLUENZAE; IMMUNOGLOBULIN D; LIPOPROTEIN; OPSONIN; VACCINE;

ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; MALE; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SEROTYPE; BLOOD; CLASSIFICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; IMMUNIZATION; IMMUNOLOGY; MENINGOCOCCOSIS; METABOLISM; MICROBIOLOGY; PNEUMOCOCCAL INFECTION; RANDOMIZED CONTROLLED TRIAL; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION;

ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CARRIER PROTEINS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN D; INFANT; LIPOPROTEINS; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 65549164676     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318199f609     Document Type: Article

References (39)

1. Tzanakaki G, Mastrantonio P. Aetiology of bacterial meningitis and resistance to antibiotics of causative pathogens in Europe and in the Mediterranean region. Int J Antimicrob Agents. 2007;29:621- 629.
2. Akkoyunlu M, Ruan M, Forsgren A. Distribution of protein D, an immunoglobulin D-binding protein, in Haemophilus strains. Infect Immun. 1991; 59:1231-1238.
3. Janson H, Ruan M, Forsgren A. Limited diversity of the protein D gene (hpd) among encapsulated and nonencapsulated Haemophilus influenzae strains. Infect Immun. 1993;61:4546-4552.
4. Munson RS Jr, Sasaki K. Protein D, a putative immunoglobulin D-binding protein produced by Haemophilus influenzae, is glycerophosphodiester phosphodiesterase. J Bacteriol. 1993;175:4569-4571.
5. Song XM, Forsgren A, Janson H. The gene encoding protein D (hpd) is highly conserved among Haemophilus influenzae type b and nontypeable strains. Infect Immun. 1995;63:696-699.
6. Janson H, Melhus A, Hermansson A, et al. Protein D, the glycerophosphodiester phosphodiesterase from Haemophilus influenzae with affinity for human immunoglobulin D, influences virulence in a rat otitis model. Infect Immun. 1994;62:4848-4854.
7. Janson H, Carle'n B, Cervin A, et al. Effects on the ciliated epithelium of protein D-producing and -nonproducing nontypeable Haemophilus influenzae in nasopharyngeal tissue cultures. J Infect Dis. 1999;180: 737-746.
8. Kilpi T, Herva E, Kaijalainen T, et al. Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life. Pediatr Infect Dis J. 2001;20:654-662.
9. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403- 409.
10. Rosenblut A, Santolaya ME, Gonzalez P, et al. Bacterial and viral etiology of acute otitis media in Chilean children. Pediatr Infect Dis J. 2001;20: 501-507.
11. Arguedas A, Dagan R, Soley C, et al. Microbiology of otitis media in Costa Rican children, 1999 through 2001. Pediatr Infect Dis J. 2003;22:1063- 1068.
12. Leibovitz E, Satran R, Piglansky L, et al. Can acute otitis media caused by Haemophilus influenzae be distinguished from that caused by Streptococcus pneumoniae? Pediatr Infect Dis J. 2003;22:509 -514.
13. Leibovitz E, Jacobs MR, Dagan R. Haemophilus influenzae: a Significant pathogen in acute otitis media. Pediatr Infect Dis J. 2004;23:1142- 1152.
14. Arguedas A, Dagan R, Guevara S, et al. Middle ear fluid Streptococcus pneumoniae serotype distribution in Costa Rican children with otitis media. Pediatr Infect Dis J. 2005;24:631- 634.
15. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D provide protection against otitis media caused by both Streptococcus pneumoniae and nontypeable Haemophilus influenzae: a randomized double blind efficacy study. Lancet. 2006;367: 740-748.
16. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:187-195.
17. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomized trial. Lancet. 2003;362:355-361.
18. Jo'dar L, Butler J, Carlone G, et al. Serological criteria for evaluations and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine. 2003;21:3265-3272.
19. Lee LH, Frasch CE, Falk LA, et al. Correlates of immunity for pneumococcal conjugate vaccines. Vaccine. 2003;21:2190 -2196.
20. World Health Organization. Pneumococcal conjugate vaccines. Recommendations for production and control of pneumococcal conjugate vaccines. WHO Tech Rep Ser. 2005;927(annex 2):64 -98.
21. Tejedor JC, Moro M, Merino JM, et al. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age. Pediatr Infect Dis J. 2008;27:579 -588.
22. Chevallier B, Vesikari T, Brzostek J, et al. Safety and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) when co-administered with routine childhood vaccines. Pediatr Infect Dis J. In press.
23. Concepcion N, Frasch NE. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2001; 8:266 -272.
24. Henckaerts I, Goldblatt D, Ashton L, et al. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with or without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol. 2006;13:356 -360.
25. Quataert SA, Kirch CS, Quackenbush-Wiedl LJ, et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 1995;2:590 -597.
26. Centers for Disease Control and Prevention and Emory University. Streptococcus pneumoniae opsonophagocytosis using differentiated HL-60 cells (Promyelocytic Leukemia Cell Line). Laboratory protocol. Available at: http://www.vaccine.uab.edu. Accessed February 17, 2006.
27. Romero-Steiner S, Frash C, Concepcion N, et al. Multi-laboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of. Streptococcus pneumoniae Clin Diagn Lab Immunol. 2003;10:1019 -1024.
28. Henckaerts I, Durant N, De Grave D, et al. Validation of a routine pneumococcal opsonophagocytosis assays to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine. 2007;25:2518-2527.
29. Knuf M, Szenborn L, Moro M, et al. Immunogenicity of routinely used childhood vaccines when co-administered with the 10-valent pneumococcal nontypeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J. In press.
30. Peeters C, Tenenbergen-Meekes AM, Poolman J, et al. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun. 1991;59:3504 -3510.
31. Granoff D, Holmes S, Belshe R, et al. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. JAMA. 1994;272:1116 -1121.
32. Kurikka S, Käyhty H, Saarinen L, et al. Immunologic priming by one dose of Haemophilus influenzae type b conjugate vaccine in infancy. J Infect Dis. 1995;172:1268 -1272.
33. Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30:100 -121.
34. Kieninger DM, Kueper K, Steul K, et al. Safety and immunologic noninferiority of 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine vaccines in healthy infants. Presented at: the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting; October 25-28, 2008; Washington, DC. Abstract G-2217.
35. Grimprel E, Scott D, Laudat F, et al; PCV Multicenter Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccination to healthy infants in France. Presented at: Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting; October 25-28, 2008; Washington, DC. Abstract G-2219.
36. PneumoADIP. Global serotype distribution summary report (Stage 1, Version 1). Available at:http://www.preventpneumo.org/pdf/GSP%20Summary% 20for%20SAGE%20Nov6-8%202007-Oct%2019-07.pdf. Accessed October 18, 2007.
37. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495-1502.
38. Hausdorff WP, Beckers F, Dagan R, et al. Estimation of the direct impact of a 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) candidate against invasive pneumococcal disease (IPD). Presented at: International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); June 9-12, 2008; Reykjavik, Iceland. Abstract P4-037.
39. Prevenar summary of product characteristics. Available at: http://www. emea.europa.eu/humandocs/Humans/EPAR/prevenar/prevenar.htm.